

## INHIBITION OF COW'S MILK XANTHINE OXIDASE BY FLAVONOIDS

TOSHIMITSU HAYASHI,\* KAZUKO SAWA,<sup>1</sup> MASARU KAWASAKI, MUNEHISA ARISAWA,  
 MINEO SHIMIZU, and NAOKATA MORITA

Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University,  
 2630 Sugitani, Toyama 930-01, Japan

Flavonoids, a large group of naturally occurring pigments, are widely distributed in the plant kingdom. They are known to inhibit a number of enzymes such as phosphodiesterase (1-3), Ca<sup>2+</sup> ATPase (4), aldose reductase (5-7), lipoxygenase (8,9), and cyclooxygenase (10). The inhibition of xanthine oxidase (xanthine: oxygen oxidoreductase, EC 1.2.3.2) by flavonoids has also been reported by several workers (11-15). The major function of this enzyme is to oxidize hypoxanthine and xanthine to uric acid. An inhibitor of xanthine oxidase has been expected to be a therapeutic agent for hyperuricemia that causes gout (16), renal stones (16,17), or ischemic myocardium (18). Allopurinol is a potent inhibitor of xanthine oxidase that has been clinically used (19). The present paper describes inhibition of xanthine oxidase from cow's milk by 103 flavonoids. Some structure-activity relationships are also discussed.

### RESULTS AND DISCUSSION

The inhibitory activities of 103 flavonoids against xanthine oxidase at 50 µg/ml were measured. The inhibition percentages of individual flavonoids excluding 19 compounds previously reported (11-15) are presented in Tables 1-5. IC<sub>50</sub>'s are also listed with flavonoids indicating more than 50% inhibition at 50 µg/ml. Baicalein, robinetin, and 3,6-dimethoxyapigenin were newly found to possess a strong inhibitory effect on xanthine oxidase. Luteolin, diosmetin, quercetin, and naringenin were confirmed to possess strong activity, and 3,6-dimethoxyapigenin showed the highest activity. Generally speaking, flavones and flavonols without a glycosyl group were relatively strong inhibitors. As Iio *et al.* reported (14), the presence of a glycosyl group decreased the inhibitory activity. Methylation of an aromatic hydroxyl group also decreased inhibition except for diosmetin

TABLE 1. Inhibitory Activities of Flavones on Xanthine Oxidase.

Compound <sup>a</sup>	Substituents						Inhibition (% at 50 µg/ml)	IC <sub>50</sub> (µM)
	5	6	7	8	3'	4'		
cosmosiin . . . . .	OH		O-R <sub>1</sub>			OH	13.9	—
rhoifolin . . . . .	OH		O-R <sub>2</sub>			OH	12.9	—
acacetin . . . . .	OH		OH			OMe	55.7	14.1
acaciin . . . . .	OH		O-R <sub>2</sub>			OMe	15.1	—
tilianine . . . . .	OH		O-R <sub>1</sub>			OMe	0	—
baicalein . . . . .	OH	OH	OH				85.5	3.3
baicalein-Me <sub>3</sub> . . . . .	OMe	OMe	OMe				22.0	—
scutellarein . . . . .	OH	OH	OH			OH	67.3	12.6
scutellarin . . . . .	OH	OH	O-R <sub>3</sub>			OH	16.6	—
cirsimaritin . . . . .	OH	OMe	OMe			OH	0	—
cirsimaritin . . . . .	OH	OMe	OMe			O-R <sub>1</sub>	12.2	—
pectolinarigenin . . . . .	OH	OMe	OH			OMe	32.1	—
pectolinarin . . . . .	OH	OMe	O-R <sub>2</sub>			OMe	11.5	—

<sup>1</sup>Née Sekino.

TABLE 1. Continued.

Compound <sup>a</sup>	Substituents						Inhibition (% at 50 µg/ml)	IC <sub>50</sub> (µM)
	5	6	7	8	3'	4'		
scutellarein-Ac <sub>4</sub> . . . . .	OAc	OAc	OAc			OAc	0	—
luteolin-7-R <sub>1</sub> . . . . .	OH		O-R <sub>1</sub>		OH	OH	67.2	75.9
lonicerin . . . . .	OH		O-R <sub>2</sub>		OH	OH	20.1	—
chrysoeriol . . . . .	OH		OH		OMe	OH	61.5	14.0
chrysoeriol-7-R <sub>3</sub> . . . . .	OH		O-R <sub>3</sub>		OMe	OH	0.3	—
diosmetin-7-R <sub>4</sub> . . . . .	OH		O-R <sub>4</sub>		OH	OMe	30.5	—
diosmetin-7-R <sub>1</sub> . . . . .	OH		O-R <sub>1</sub>		OH	OMe	28.9	—
diosmin . . . . .	OH		O-R <sub>2</sub>		OH	OMe	0	—
luteolin-Ac <sub>4</sub> . . . . .	OAc		OAc		OAc	OAc	47.7	—
pedaltin . . . . .	OH	OMe	OH		OH	OH	49.0	—
cirsiliol . . . . .	OH	OMe	OMe		OH	OH	0.5	—
cirsiliol-4'-R <sub>1</sub> . . . . .	OH	OMe	OMe		OH	O-R <sub>1</sub>	0	—
cirsileneol . . . . .	OH	OMe	OMe		OMe	OH	1.0	—
cirsileneol-4'-R <sub>1</sub> . . . . .	OH	OMe	OMe		OMe	O-R <sub>1</sub>	0	—
wogonin . . . . .	OH	R	OH	OMe			50.2	176.1
fukugetin . . . . .	OH	R	OH		OH	OH	97.2	22.3
flavone . . . . .							15.4	—

<sup>a</sup>R = -CO-CH-CH-Ph-OH, R<sub>1</sub> = glucose, R<sub>2</sub> = rhamnose-glucose, R<sub>3</sub> = glucuronic acid, R<sub>4</sub> = arabinose-glucose.

and 3,6-dimethoxyapigenin. All acetates, isoflavones, and C-glycosylflavonoids tested showed less inhibitory activity. Recently, Nishibe *et al.* found 4'-O-glycosylated flavonoids with po-

tent inhibitory activity (15). These findings suggested the presence of free hydroxyl groups at C-5 and C-7 to be important for producing inhibitory activity against xanthine oxidase. In the

TABLE 2. Inhibitory Activities of Flavonols on Xanthine Oxidase.

Compound <sup>a</sup>	Substituents								Inhibition (% at 50 µg/ml)	IC <sub>50</sub> (µM)
	3	5	6	7	3'	4'	5'	2"		
trifolin . . . . .	O-R <sub>3</sub>	OH		OH		OH			16.1	—
kaempferitrin . . . . .	O-R <sub>6</sub>	OH		O-R <sub>6</sub>		OH			15.5	—
juglanin . . . . .	O-R <sub>7</sub>	OH		OH		OH			0	—
kaempferol-7-R <sub>1</sub> . . . . .	OH	OH		O-R <sub>1</sub>		OH			0	—
kaempferol-3-R <sub>2</sub> . . . . .	O-R <sub>2</sub>	OH		OH		OH			14.4	—
hyperin . . . . .	O-R <sub>3</sub>	OH		OH	OH	OH			43.0	—
quercetin-3-R <sub>3</sub> . . . . .	O-R <sub>3</sub>	OH		OH	OH	OH			36.5	—
reynoutrin . . . . .	O-R <sub>8</sub>	OH		OH	OH	OH			33.1	—
avicularin . . . . .	O-R <sub>7</sub>	OH		OH	OH	OH			30.8	—
quercetin-3-R <sub>1</sub> -2"-R <sub>9</sub> . . . . .	O-R <sub>1</sub>	OH		OH	OH	OH	C-R <sub>9</sub>		21.0	—
quercimeritrin . . . . .	OH	OH		O-R <sub>1</sub>	OH	OH			0	—
quercetin-3-Me . . . . .	OMe	OH		OH	OH	OH			98.5	31.6
quercetin-3-Me-4'-R <sub>1</sub> . . . . .	OMe	OH		OH	OH	O-R <sub>1</sub>			69.1	35.6
quercetin-3-Me-7-R <sub>1</sub> . . . . .	OMe	OH		O-R <sub>1</sub>	OH	OH			39.5	—
isorhamnetin . . . . .	OH	OH		OH	OMe	OH			49.0	—
persicarin . . . . .	O-KSO <sub>3</sub>	OH		OH	OMe	OH			90.3	34.6
narcissin . . . . .	O-R <sub>2</sub>	OH		OH	OMe	OH			22.2	—
quercetin-Ac <sub>5</sub> . . . . .	OAc	OAc		OAc	OAc	OAc			0	—
myricetin-3-R <sub>10</sub> . . . . .	O-R <sub>10</sub>	OH		OH	OH	OH	OH	OAc	88.6	19.1
myricetin-Ac <sub>6</sub> . . . . .	OAc	OAc		OAc	OAc	OAc			13.6	—
robinetin . . . . .	OH			OH	OH	OH	OH		82.9	4.3
apigenin-3,6-OMe <sub>2</sub> . . . . .	OMe	OH	OMe	OH		OH			95.0	0.03

<sup>a</sup>R<sub>1</sub> = glucose, R<sub>2</sub> = rhamnose-glucose, R<sub>3</sub> = glucuronic acid, R<sub>4</sub> = galactose, R<sub>6</sub> = rhamnose, R<sub>7</sub> = arabinose, R<sub>8</sub> = xylose, R<sub>9</sub> = gallic acid, R<sub>10</sub> = rhamnose-galactose.

TABLE 3. Inhibitory Activities of Flavanones, Flavanonols, and Isoflavones on Xanthine Oxidase.

Compound <sup>a</sup>	Substituents <sup>a</sup>								Inhibition (% at 50 µg/ml)	IC <sub>50</sub> (µM)
	3	5	6	7	8	3'	4'	5'		
<i>Flavanone</i>										
liquiritigenin . . . . .				OH			OH		100	11.3
liquiritin . . . . .				OH			O-R <sub>1</sub>		18.0	—
prunin . . . . .		OH		O-R <sub>1</sub>			OH		4.2	—
sakuranetin . . . . .		OH		OMe			OH		0	—
isosakuranetin . . . . .		OH		OH			OMe		0	—
poncitrin . . . . .		OH		O-R <sub>2</sub>			OMe		0	—
eriodictyol . . . . .		OH		OH		OH	OH		47.8	—
<i>Flavanonol</i>										
aromadendrin . . . . .	OH	OH		OH			OH		66.9	93.8
fustin . . . . .	OH			OH		OH	OH		27.2	—
taxifolin . . . . .	OH	OH		OH		OH	OH		17.8	—
astilbin . . . . .	O-R <sub>6</sub>	OH		OH		OH	OH		0	—
phellamurin . . . . .	OH	OH		O-R <sub>1</sub>	R <sub>11</sub>		OH		0	—
<i>Isoflavone</i>										
daidzein . . . . .				OH			OH		0	—
daidzin . . . . .				O-R <sub>1</sub>			OH		0	—
formononetin . . . . .				OH			OMe		17.6	—
genistein . . . . .		OH		OH			OH		0	—
genistin . . . . .		OH		O-R <sub>1</sub>			OH		0.8	—
sophoricoside . . . . .		OH		OH			O-R <sub>1</sub>		15.3	—
tectorigenin . . . . .		OH	OMe	OH			OH		0	—
tectoridin . . . . .		OH	OMe	O-R <sub>1</sub>			OH		0	—
iristectorigenin A . . . . .		OH	OMe	OH		OH	OMe		0	—
irigenin . . . . .		OH	OMe	OH		OH	OMe	OMe	0	—
iridin . . . . .		OH	OMe	O-R <sub>1</sub>		OH	OMe	OMe	0	—
irisolone . . . . .		OMe	-O-CH <sub>2</sub> -O-				OH		0	—
irisflorentin . . . . .		OMe	-O-CH <sub>2</sub> -O-			OMe	OMe	OMe	0	—

<sup>a</sup>R<sub>1</sub> = glucose, R<sub>2</sub> = rhamnose-glucose, R<sub>6</sub> = rhamnose, R<sub>11</sub> = -(CH<sub>2</sub>)<sub>2</sub>-C(OH)(CH<sub>3</sub>)<sub>2</sub>.

cases of vitexin and orientin possessing free OH at C-5 and C-7, the C-glycosyl group might be too bulky and prevent the flavonoids from combining with the enzyme. The lack of activity of isoflavones and 3-O-glycosylated flavonols with a free OH at C-5 and C-7 seemed to


be due to the steric factor of the bulky group at C-3. The low activity of flavanones and flavanonols suggested the presence of a double bond between C-2 and C-3 to be an important factor. The high activity of diosmetin (IC<sub>50</sub> 0.07 µM) and 3,6-dimethoxyapigenin (IC<sub>50</sub>

TABLE 4. Inhibitory Activities of C-glycosylflavonoids on Xanthine Oxidase.

Compound <sup>a</sup>	Substituent <sup>a</sup>								Inhibition (% at 50 µg/ml)
	3	5	6	7	8	3'	4'	2''	
vitexin . . . . .		OH		OH	C-R <sub>1</sub>		OH		0
orientin . . . . .		OH		OH	C-R <sub>1</sub>	OH	OH		15.3
isoorientin . . . . .		OH	C-R <sub>1</sub>	OH		OH	OH		25.2
isoorientin-7-R <sub>1</sub> . . . . .		OH	C-R <sub>1</sub>	O-R <sub>1</sub>		OH	OH		0
swertisin . . . . .		OH	C-R <sub>1</sub>	OMe			OH		24.9
embigenin . . . . .		OH	C-R <sub>1</sub>	OMe			OMe		33.5
embinin . . . . .		OH	C-R <sub>1</sub>	OMe			OMe	O-R <sub>6</sub>	22.8
keyakinin . . . . .	OH	OH	C-R <sub>1</sub>	OMe			OH		0

<sup>a</sup>R<sub>1</sub> = glucose, R<sub>6</sub> = rhamnose.

TABLE 5. Inhibitory Activities of Biflavones on Xanthine Oxidase.



Compound	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	Inhibition (% at 50 μg/ml)	IC <sub>50</sub> (μM)
amentoflavone . . . . .	H	H	H	H	100	35.3
sciadopitysin . . . . .	Me	Me	H	Me	0	—

0.03 μM) might be attributable to their surface activity, as Iio *et al.* suggested (14).

### EXPERIMENTAL

**MATERIAL.**—We obtained most of the flavonoids tested from plant sources; 3,6-dimethoxyapigenin was obtained through the courtesy of professor T.J. Mabry, University of Texas at Austin. Other chemicals were purchased from commercial sources and used without further purification: xanthine oxidase (Boehringer Mannheim Co. Ltd.), xanthine (ICN Pharmaceuticals Inc.), sodium phosphate dibasic 12 hydrate, potassium phosphate monobasic, and Tween 80 (Wako Pure Chemical Industries, Ltd.).

**ASSAY OF XANTHINE OXIDASE ACTIVITY.**—Xanthine oxidase activity was measured by the method reported by Noro *et al.* (13). The inhibitory activity (%) was calculated as follows:  $(1 - B/A) \times 100$ , where A is the activity of enzyme without test material, and B is the activity of enzyme with test material.

### LITERATURE CITED

- M. Ruckstuhl, A. Beretz, R. Anton, and Y. Landry, *Biochem. Pharmacol.*, **28**, 535 (1979).
- E. Perkov, N. Nikolov, and P. Uzunov, *Planta Med.*, **43**, 183 (1981).
- T. Nikaido, T. Ohmoto, T. Nomura, T. Fukai, and U. Sankawa, *Chem. Pharm. Bull.*, **32**, 4929 (1984).
- C.M.S. Fewtrell and B.D. Gomperts, *Nature*, **265**, 635 (1977).
- S.D. Varma and J.H. Kinoshita, *Biochem. Pharmacol.*, **25**, 2505 (1976).
- J. Okuda, I. Miwa, K. Inagaki, T. Horie, and M. Nakayama, *Chem. Pharm. Bull.*, **32**, 767 (1984).
- M. Shimizu, T. Ito, S. Terashima, T. Hayashi, M. Arisawa, N. Morita, S. Kurokawa, K. Ito, and Y. Hashimoto, *Phytochemistry*, **23**, 1885 (1984).
- S. Sekiya and H. Okuda, *Biochem. Biophys. Res. Commun.*, **105**, 1090 (1982).
- T. Yoshimoto, M. Furukawa, S. Yamamoto, T. Horie, and S.K. Watanabe, *Biochem. Biophys. Res. Commun.*, **116**, 612 (1983).
- J. Baumann, G. Wurm, and F.V. Bruchhausen, *Arch. Pharm. (Weinheim, Ger.)*, **313**, 330 (1980).
- J.M. Beiler and G.J. Martin, *J. Biol. Chem.*, **192**, 831 (1951).
- K. Otsuka, Y. Ogata, H. Shiojiri, Y. Wakabayashi, and K. Kagei, "Abstracts of Papers," The 103rd Annual Meeting of the Pharmaceutical Society of Japan, Tokyo, 1983, p. 221.
- T. Noro, Y. Oda, T. Miyase, A. Ueno, and S. Fukushima, *Chem. Pharm. Bull.*, **31**, 3984 (1983).
- M. Iio, A. Moriyama, Y. Matsumoto, N. Takaki, and M. Fukumoto, *Agric. Biol. Chem.*, **49**, 2173 (1985).
- S. Nishibe, A. Sakushima, T. Noro, and S. Fukushima, *Shoyakugaku Zasshi*, **41**, 116 (1987).
- A.P. Hall, P.E. Barry, T.R. Dawber, and P.M. McNamara, *Am. J. Med.*, **42**, 27 (1967).
- T.F. Yü and A.B. Gutman, *Ann. Int. Med.*, **67**, 1133 (1967).
- R.A. DeWall, K.A. Vasko, E.L. Stanley, and P. Kezdi, *Am. Heart J.*, **82**, 362 (1971).
- A.G. Gilman, L.S. Goodman, T.W. Rall, and F. Murad, "Goodman and Gilman's The Pharmacological Basis of Therapeutics," Macmillan, New York, 7th ed., 1985, p. 712.

Received 28 August 1987